138 related articles for article (PubMed ID: 25189490)
1. The incidence and clinical predictors of ACE-inhibitor induced dry cough by perindopril in 27,492 patients with vascular disease.
Brugts JJ; Arima H; Remme W; Bertrand M; Ferrari R; Fox K; DiNicolantonio J; MacMahon S; Chalmers J; Zijlstra F; Caliskan K; Simoons ML; Mourad JJ; Boersma E; Akkerhuis KM
Int J Cardiol; 2014 Oct; 176(3):718-23. PubMed ID: 25189490
[TBL] [Abstract][Full Text] [Related]
2. Dechallenge and rechallenge method showed different incidences of cough among four ACE-Is.
Tumanan-Mendoza BA; Dans AL; Villacin LL; Mendoza VL; Rellama-Black S; Bartolome M; Ragual J; Flor B; Valdez J
J Clin Epidemiol; 2007 Jun; 60(6):547-53. PubMed ID: 17493508
[TBL] [Abstract][Full Text] [Related]
3. The consistency of the treatment effect of an ACE-inhibitor based treatment regimen in patients with vascular disease or high risk of vascular disease: a combined analysis of individual data of ADVANCE, EUROPA, and PROGRESS trials.
Brugts JJ; Ninomiya T; Boersma E; Remme WJ; Bertrand M; Ferrari R; Fox K; MacMahon S; Chalmers J; Simoons ML
Eur Heart J; 2009 Jun; 30(11):1385-94. PubMed ID: 19346520
[TBL] [Abstract][Full Text] [Related]
4. Frequency of cough during therapy with ACE inhibitors in Greek hypertensives.
Efstratopoulos AD; Meikopoulos M; Voyaki S
J Hum Hypertens; 1993 Dec; 7(6):607-9. PubMed ID: 8114058
[TBL] [Abstract][Full Text] [Related]
5. ACE inhibitors and cough.
Yeşil S; Yeşil M; Bayata S; Postaci N
Angiology; 1994 Sep; 45(9):805-8. PubMed ID: 8092546
[TBL] [Abstract][Full Text] [Related]
6. Angiotensin-converting enzyme inhibition by perindopril in the treatment of cardiovascular disease.
Brugts JJ; Ferrari R; Simoons ML
Expert Rev Cardiovasc Ther; 2009 Apr; 7(4):345-60. PubMed ID: 19379059
[TBL] [Abstract][Full Text] [Related]
7. Angiotensin-converting enzyme inhibitor-induced cough: ACCP evidence-based clinical practice guidelines.
Dicpinigaitis PV
Chest; 2006 Jan; 129(1 Suppl):169S-173S. PubMed ID: 16428706
[TBL] [Abstract][Full Text] [Related]
8. An evaluation of risk factors for adverse drug events associated with angiotensin-converting enzyme inhibitors.
Morimoto T; Gandhi TK; Fiskio JM; Seger AC; So JW; Cook EF; Fukui T; Bates DW
J Eval Clin Pract; 2004 Nov; 10(4):499-509. PubMed ID: 15482412
[TBL] [Abstract][Full Text] [Related]
9. Association of polymorphisms of the renin-angiotensin system and bradykinin B2 receptor with ACE-inhibitor-related cough.
Mukae S; Itoh S; Aoki S; Iwata T; Nishio K; Sato R; Katagiri T
J Hum Hypertens; 2002 Dec; 16(12):857-63. PubMed ID: 12522467
[TBL] [Abstract][Full Text] [Related]
10. The safety and acceptability of perindopril.
Brown CL
J Hum Hypertens; 1990 Oct; 4 Suppl 4():51-5; discussion 55-6. PubMed ID: 2283654
[TBL] [Abstract][Full Text] [Related]
11. Modulation of the renin-angiotensin-aldosterone system and cough.
Lacourcière Y; Lefebvre J
Can J Cardiol; 1995 Aug; 11 Suppl F():33F-39F. PubMed ID: 7664216
[TBL] [Abstract][Full Text] [Related]
12. Severe nonproductive cough and cough-induced stress urinary incontinence in diabetic postmenopausal women treated with ACE inhibitor.
Lee YJ; Chiang YF; Tsai JC
Diabetes Care; 2000 Mar; 23(3):427-8. PubMed ID: 10868884
[No Abstract] [Full Text] [Related]
13. Cough and ACE inhibitors.
Simon SR; Black HR; Moser M; Berland WE
Arch Intern Med; 1992 Aug; 152(8):1698-700. PubMed ID: 1497404
[TBL] [Abstract][Full Text] [Related]
14. Comparison of Clinical Factors Between Patients With Angiotensin-Converting Enzyme Inhibitor-Induced Angioedema and Cough.
Hallberg P; Nagy J; Karawajczyk M; Nordang L; Islander G; Norling P; Johansson HE; Kämpe M; Hugosson S; Yue QY; Wadelius M
Ann Pharmacother; 2017 Apr; 51(4):293-300. PubMed ID: 27889699
[TBL] [Abstract][Full Text] [Related]
15. The impact of age and sex on the reporting of cough and angioedema with renin-angiotensin system inhibitors: a case/noncase study in VigiBase.
Alharbi FF; Kholod AAV; Souverein PC; Meyboom RH; de Groot MCH; de Boer A; Klungel OH
Fundam Clin Pharmacol; 2017 Dec; 31(6):676-684. PubMed ID: 28767167
[TBL] [Abstract][Full Text] [Related]
16. Pharmacogenetic predictors of angiotensin-converting enzyme inhibitor-induced cough: the role of ACE, ABO, and BDKRB2 genes.
Mas S; Gassò P; Alvarez S; Ortiz J; Sotoca JM; Francino A; Carne X; Lafuente A
Pharmacogenet Genomics; 2011 Sep; 21(9):531-8. PubMed ID: 21832968
[TBL] [Abstract][Full Text] [Related]
17. High prevalence of persistent cough with angiotensin converting enzyme inhibitors in Chinese.
Woo KS; Nicholls MG
Br J Clin Pharmacol; 1995 Aug; 40(2):141-4. PubMed ID: 8562296
[TBL] [Abstract][Full Text] [Related]
18. The combined cough frequency/severity scoring: a new approach to cough evaluation in clinical settings.
Fisman EZ; Shapira I; Motro M; Pines A; Tenenbaum A
J Med; 2001; 32(3-4):181-7. PubMed ID: 11563816
[TBL] [Abstract][Full Text] [Related]
19. Rate of Cough During Treatment With Angiotensin-Converting Enzyme Inhibitors: A Meta-Analysis of Randomized Placebo-Controlled Trials.
Vukadinović D; Vukadinović AN; Lavall D; Laufs U; Wagenpfeil S; Böhm M
Clin Pharmacol Ther; 2019 Mar; 105(3):652-660. PubMed ID: 29330882
[TBL] [Abstract][Full Text] [Related]
20. Quality of life and cough on antihypertensive treatment: a randomised trial of eprosartan, enalapril and placebo.
Rake EC; Breeze E; Fletcher AE
J Hum Hypertens; 2001 Dec; 15(12):863-7. PubMed ID: 11773989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
